Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.

Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Abstract Text:

BACKGROUND: Most patients with primary epithelial ovarian cancer (PEOC) treated with carboplatin/paclitaxel will relapse between one to two years. Our purpose was to define the optimal calculation method for the adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) applied to PEOC treated with platinum-containing chemotherapy and to analyze its predictive relevance. MATERIALS AND METHODS: ATP-TCA results from 80 PEOC specimens were analyzed applying three different methods: 50% inhibition concentration, sensitivity index (IndexSUM), and area under curve by testing multiple cut-off levels. Correlation between in vitro results and clinical outcome was performed for 61 (76%) patients by univariative and multivariative analysis. Tumor recurrence 6 months after chemotherapy was classified as platinum-resistance. RESULTS: The IndexSUM set at > 250 had the highest test sensitivity, specificity, positive and negative predictive value of 90%, 43%, 62% and 81%, respectively. Patients whose tumors were shown to be resistant by ATP-TCA had a higher risk for recurrence (RR) compared to those who tested as sensitive (p < 0.003, RR = 3.3, 95% CI = 1.2-9.4). This result was confirmed after adjustment for FIGO stage by logistic regression (p < 0.004, Odds ratio = 8.3, 95% CI = 1.9-35.5). In multivariate analysis ATP-TCA and the FIGO-stage were independent predictive factors of early recurrence. CONCLUSION: ATP-TCA results in combination with the use of IndexSUM > 250 are best able to predict platinum resistance.

Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Anticancer research

VOLUME: 28

Page Numbers: 949-55

Journal Abbreviation: Anticancer Res.

ISSN: 0250-7005

DAY: 29

MONTH: 05

YEAR: 2008

Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8102988

Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.

AFFILIATION: Department of Obstetrics and Gynecology, University of Tuebingen, 72076 Tuebingen, Germany. Hans.Neubauer@med.uni-tuebingen.de

Country: Greece

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Anticancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer Related Publications

• Acute twin-twin transfusion syndrome: a case report.
• Changes in tumour biological markers during primary systemic chemotherapy (PST).
• Disturbed cortisol secretion in man: contrasting Cushing's disease and endogenous depression.
• Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10.
• Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients.
• Epidemiology and natural course of social fears and social phobia.
• Glucocorticoid influences on the auditory brain-stem responses in man.
• Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
• Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients.
• Tumor cell dormancy: implications for the biology and treatment of breast cancer.